Sage Therapeutics, Inc. — Revenue by Fiscal Year
7 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/208b7726-a638-4dac-82db-aab000c8c57b/serie/revenue
| Fiscal year | Revenue | Period | Evidence |
|---|---|---|---|
| FY 2024 | $41.2M | 2024-01-01 – 2024-12-31 | evidence 0000950170-25-017909 |
| FY 2023 | $86.5M | 2023-01-01 – 2023-12-31 | evidence 0000950170-24-014934 |
| FY 2022 | $7.7M | 2022-01-01 – 2022-12-31 | evidence 0000950170-23-002964 |
| FY 2021 | $6.3M | 2021-01-01 – 2021-12-31 | evidence 0001564590-22-006495 |
| FY 2020 | $1.1B | 2020-01-01 – 2020-12-31 | evidence 0001564590-21-007819 |
| FY 2019 | $6.9M | 2019-01-01 – 2019-12-31 | evidence 0001564590-20-007021 |
| FY 2018 | $90.3M | 2018-01-01 – 2018-12-31 | evidence 0001564590-19-003191 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
Sage Therapeutics, Inc. — all facts · Net Income · Operating Income